SWK (NASDAQ:SWKH) Shares Down 4.1% – Time to Sell?

Shares of SWK Holdings Co. (NASDAQ:SWKH) were down 4.1% during trading on Friday . The company traded as low as $15.63 and last traded at $15.80. Approximately 67,931 shares were traded during trading, an increase of 530% from the average daily volume of 10,786 shares. The stock had previously closed at $16.47.

SWK Stock Performance

The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.11. The stock has a market cap of $193.28 million, a price-to-earnings ratio of 16.99 and a beta of 0.35. The firm’s 50-day moving average is $16.36 and its two-hundred day moving average is $16.80.

Hedge Funds Weigh In On SWK

Hedge funds and other institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new position in SWK in the 3rd quarter valued at $589,000. SkyView Investment Advisors LLC increased its position in SWK by 7.7% during the second quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock worth $529,000 after purchasing an additional 2,234 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in SWK by 85.7% in the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock valued at $511,000 after acquiring an additional 13,892 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in SWK during the second quarter worth about $172,000. Finally, Barclays PLC boosted its position in shares of SWK by 185.0% during the third quarter. Barclays PLC now owns 4,461 shares of the company’s stock worth $77,000 after buying an additional 2,896 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About SWK

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.